GSK-461364 (GSK461364; GSK 461364) is a novel, potent, selective, reversible and ATP-competitive small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antitumor activity.

TAK-960 DiHCl, the dihydrochloride salt of TAK960, is an orally bioavailable, potent, and selective PLK1 polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.8 nM at 10 μM ATP.

CFI400945 is a potent, selective, and orally bioavailable PLK4 (polo-like kinase 4) inhibitor with IC50 value of 2.8 ±1.4 nM and potential antineoplastic activity.

Centrinone-B (LCR323; LCR-323; LCR 323) is a novel and reversible polo-like kinase 4 (PLK4) inhibitor with potential anticancer activity.

Rigosertib (formerly also known as ON-01910) is a novel, potent and non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay.

BI2536 (BI-2536; BI 2536) is a novel PLK1/BRD4 dual inhibitor with potential antitumor activity.

HMN-214 (HMN 214; HMN214), stilbene derivative, is a potent and orally bioactive prodrug of HMN-176, which alters the cellular spatial orientation of Plk1 (polo-like kinase-1).

3MB-PP1, also known as 3-MB-PP1, 3 MB-PP1, is a Polo-like kinase 1 (PLK1) inhibitor.

SBE 13 HCl (SBE13; SBE-13), the hydrochloride salt of SBE13, is a novel, potent and selective Polo-like Kinase 1 (PLK1) inhibitor with potential antineoplastic activity.

RO3280 (also known as Ro-5203280; RO 3280; Ro5203280; RO-3280) is a novel, potent and highly selective inhibitor of Polo-like kinase 1 (PLK1) with potential anticancer activity.